Epidemiologic Features and Containment of
SARS-CoV-2 Omicron Variant

doi:10.12114/j.issn.1007-9572.2021.00.348

Abstract

Abstract:

Since the first case of the Omicron (B.1.1.529) variant discovered in South Africa was reported to the WHO on November 24, 2021, a total of 57 countries (regions) had reported Omicron cases as of December 8, 2021. Omicron has become the dominant strain in some African countries and is spreading rapidly. Although Omicron causes mild symptoms, with most cases being asymptomatic and mild, the rapid increase in the number of cases could put a heavy strain on global health systems. In addition, its source, transmission characteristics and vaccine resistance remain unclear, which brings great challenges to pandemic prevention and control in all countries (regions) . We reviewed the latest developments in etiological characteristics, mutation sources, transmission characteristics and possible mechanisms, pandemic status, vaccine protection effect and containment measures regarding Omicron, providing a reference for scientific containment of Omicron mutant.

Key words: SARS-CoV-2, Omicron variants of concern, COVID-19, Epidemiology, Review

摘要：

Omicron（B.1.1.529）变异株于2021年11月24日首次从南非报告给世界卫生组织，截至2021年12月8日全球共有57个国家和地区报告了Omicron感染病例。目前Omicron变异株在部分非洲国家已成为主导毒株，且传播速度快。尽管Omicron变异株引起的疾病症状较轻，多数病例为无症状感染者和轻型患者，但病例数量的快速增长可能给全球卫生系统带来沉重压力。此外，Omicron变异株的变异来源、传播特征、疫苗抗性等尚不明确，给各国和地区的疫情防控带来很大挑战。本文就Omicron变异株的病原学特征、变异来源、传播特征及可能的机制、流行现状、疫苗对其保护效果、防控措施等方面的研究进展进行综述，以期为科学防控Omicron变异株所致疫情提供参考。

关键词: 新型冠状病毒, Omicron关切变异株, 新型冠状病毒肺炎, 流行病学, 综述

CLC Number:

R373.1

WU Yu, LIU Jue, LIU Min, LIANG Wannian.

Epidemiologic Features and Containment of SARS-CoV-2 Omicron Variant [J]. Chinese General Practice, 2022, 25(01): 14-19.

吴俣,刘珏,刘民等. 新型冠状病毒Omicron变异株的流行病学特征及防控研究[J]. 中国全科医学, 2022, 25(01): 14-19. DOI: 10.12114/j.issn.1007-9572.2021.00.348.

References 47

[1]	WHO. Coronavirus（COVID-19） dashboard[EB/OL]. （2021-12-13）[2021-12-13]. .
[2]	WHO. Tracking SARS-CoV-2 variants[EB/OL]. （2021-12-06）[2021-12-09]. .
[3]	WHO. Classification of Omicron（B.1.1.529）：SARS-CoV-2 variant of concern[EB/OL]. （2021-11-26）[2021-12-09]. .
[4]	天津市卫生健康委员会. 天津从入境人员中检出新冠病毒奥密克戎变异株，为中国内地首次检出[EB/OL]. （2021-12-14）[2021-12-14]. .
[5]	香港特别行政区政府卫生署. 卫生防护中心调查新增六宗2019冠状病毒病确诊个案及汇报输入个案12388及12404调查进展[EB/OL]. （2021-11-25）[2021-12-09]. .
[6]	GU H, KRISHNAN P, NG D Y M，et al. Probable transmission of SARS-CoV-2 Omicron variant in Quarantine Hotel，Hong Kong，China，November 2021[J]. Emerg Infect Dis，2021，28(2):212422. DOI：10.3201/eid2802.212422.
[7]	国家卫生健康委员会办公厅，国家中医药管理局办公室. 新型冠状病毒肺炎诊疗方案（试行第八版）[EB/OL]. （2020-08-18）[2021-12-09]. .
[8]	CHAN J F, KOK K H, ZHU Z，et al. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan[J]. Emerg Microbes Infec，2020，9(1):221-236. DOI：10.1080/22221751.2020.1719902.
[9]	GIOVANETTI M, BENEDETTI F, CAMPISI G，et al. Evolution patterns of SARS-CoV-2：snapshot on its genome variants[J]. Biochem Biophys Res Commun，2021，538(10):88-91. DOI：10.1016/j.bbrc.2020.10.102.
[10]	GeneTex. SARS-CoV-2 Omicron变体的突变位点[EB/OL].（2021-11-29）[2021-12-09]. .
[11]	CALLAWAY E. Heavily mutated Omicron variant puts scientists on alert[J]. Nature，2021，600(7887):21. DOI：10.1038/d41586-021-03552-w.
[12]	CHEN J H，WANG R，GILBY N B，et al. Omicron（B.1.1.529）：infectivity，vaccine breakthrough，and antibody resistance[EB/OL]. （2021-12-01）[2021-12-09]. .
[13]	KUPFERSCHMIDT K. Where did 'weird' Omicron come from[J]. Science，2021，374(6572):1179. DOI：10.1126/science.acx9754.
[14]	KARIM F，MOOSA M，GOSNELL B，et al. Persistent SARS-CoV-2 infection and intra-host evolution in association with advanced HIV infection[EB/OL]. （2021-06-04）[2021-12-09]. .
[15]	WHO. South Africa HIV country profile 2021[EB/OL]. （2021-12-01）[2021-12-09]. .
[16]	KARIM F，GAZY I，CELE S，et al. HIV status alters disease severity and immune cell responses in beta variant SARS-CoV-2 infection wave[EB/OL]. （2021-09-05）[2021-12-09]. .
[17]	CHANDLER J C, BEVINS S N, ELLIS J W，et al. SARS-CoV-2 exposure in wild white-tailed deer（Odocoileus virginianus）[J]. Proc Natl Acad Sci U S A，2021，118(47):e2114828118. DOI：10.1101/2021.07.29.454326.
[18]	ABBASI J. Omicron has reached the US：here's what infectious disease experts know about the variant[EB/OL]. （2021-12-06）[2021-12-09]. .
[19]	CALLAWAY E, LEDFORD H. How bad is Omicron? What scientists know so far[J]. Nature，2021，600(7888):197-199. DOI：10.1038/d41586-021-03614-z.
[20]	Chelsea News. The Omicron factor[EB/OL]. （2021-12-06）[2021-12-09]. .
[21]	Metaculus. Estimated R0 of Omicron variant[EB/OL]. （2021-11-27）[2021-12-09]. .
[22]	Our World in Data. Daily new confirmed COVID-19 cases[EB/OL]. （2021-12-09）[2021-12-09]. .
[23]	China Media Grand Mishmash. Omicron variant 37.5% more infectious than Delta[EB/OL]. （2021-11-30）[2021-12-09]. .
[24]	Republicworld. Omicron scare：Israeli health chiefs claim those vaccinated in last 6 months are protected[EB/OL]. （2021-12-01）[2021-12-09]. .
[25]	PULLIAM J R C，VAN SCHALKWYK C，GOVENDER N，et al. Increased risk of SARS-CoV-2 reinfection associated with emergence of the Omicron variant in South Africa[EB/OL]. （2021-12-02）[2021-12-09]. .
[26]	Cananli ANSA. Prima foto di Omicron da gruppo di ricerca Bambino Gesu'[EB/OL]. （2021-11-27）[2021-12-09]. .
[27]	QIN S, CUI M, SUN S，et al. Genome characterization and potential risk assessment of the novel SARS-CoV-2 variant Omicron（B.1.1.529）[J]. Zoonoses，2021. [Epub ahead of print]. DOI：10.15212/ZOONOSES-2021-0024.
[28]	ALI F, KASRY A, AMIN M. The new SARS-CoV-2 strain shows a stronger binding affinity to ACE2 due to N501Y mutant[J]. Med Drug Discov，2021，10:100086.
[29]	WANG W B, LIANG Y, JIN Y Q，et al. E484K mutation in SARS-CoV-2 RBD enhances binding affinity with hACE2 but reduces interactions with neutralizing antibodies and nanobodies：binding free energy calculation studies[J]. J Mol Graph Model，2021，109:108035. DOI：10.1016/j.jmgm.2021.108035.
[30]	RANI P R, IMRAN M, LAKSHMI J V，et al. Symptomatic reinfection of SARS-CoV-2 with spike protein variant N440K associated with immune escape[J]. J Med Virol，2021，93(7):4163-4165. DOI：10.31219/osf.io/7gk69.
[31]	CHAN Y A, ZHAN S H. The emergence of the spike furin cleavage site in SARS-CoV-2[J]. Mol Biol Evol，2021. [Epub ahead of print]. DOI：10.1093/molbev/msab327.
[32]	COLSON P, LEVASSEUR A, DELERCE J，et al. Spreading of a new SARS-CoV-2 N501Y spike variant in a new lineage[J]. Clin Microbiol Infect，2021，27(9):1352.e1-5. D
[33]	MOHAMMAD A, ABUBAKER J, AL-MULLA F. Structural modelling of SARS-CoV-2 alpha variant（B.1.1.7） suggests enhanced furin binding and infectivity[J]. Virus Res，2021，303:198522.
[34]	WU H, XING N, MENG K，et al. Nucleocapsid mutations R203K/G204R increase the infectivity，fitness，and virulence of SARS-CoV-2[J]. Cell Host Microbe，2021，29(12):1788-1801.
[35]	DYER O. Covid-19：South Africa's surge in cases deepens alarm over omicron variant[J]. BMJ，2021，375:n3013.
[36]	WHO. Weekly epidemiological update on COVID-19：7 December 2021[EB/OL]. （2021-12-07）[2021-12-09]. .
[37]	European Centre for Disease Prevention and Control. Epidemiological update：Omicron variant of concern（VOC）：data as of 7 December 2021（12.00）[EB/OL]. （2021-12-07）[2021-12-09]. .
[38]	CDC. Omicron variant：what you need to know[EB/OL]. （2021-12-09）[2021-12-09]. .
[39]	Eminetra. WHO：most Omicron cases are "mild" or asymptomatic，and existing vaccines need to provide protection[EB/OL]. （2021-12-03）[2021-12-09]. .
[40]	SAMRS. Tshwane District Omicron variant patient profile：early features[EB/OL]. （2021-12-04）[2021-12-09]. .
[41]	GAO S J, GUO H, LUO G. Omicron variant（B.1.1.529） of SARS-CoV-2，a global urgent public health alert[J]. J Med Virol，2022，94(1). DOI：10.1002/jmv.27491.
[42]	CELE S，JACKSON L. SARS-CoV-2 Omicron has extensive but incomplete escape of Pfizer BNT162b2 elicited neutralization and requires ACE2 for infection[EB/OL]. （2021-12-07）[2021-12-09]. .
[43]	CNBC. Pfizer and BioNTech say booster dose provides high level of protection against omicron variant in initial lab study[EB/OL]. （2021-12-08）[2021-12-09]. .
[44]	NBC. Moderna says an omicron variant vaccine could be ready in early 2022[EB/OL]. （2021-11-28）[2021-12-09]. .
[45]	Australian Government Department of Health. Additional border security measures to protect Australians from the new 'Omicron' COVID-19 variant[EB/OL]. （2021-11-27） [2021-12-09]. .
[46]	Public Health Agency of Canada. Government of Canada introduces additional measures to address COVID-19 Omicron variant of concern[EB/OL]. （2021-11-30）[2021-12-09]. .
[47]	国家卫生健康委. 关于奥密克戎，国家卫生健康委权威解答来了[EB/OL]. （2021-11-29） [2021-12-09]. .

Epidemiologic Features and Containment of SARS-CoV-2 Omicron Variant

新型冠状病毒Omicron变异株的流行病学特征及防控研究

RichHTML

PDF

Supplement

Knowledge

Abstract

Cite this article

share this article

References 47

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	WANG Xu, WEI Xu, ZHU Liguo, FENG Tianxiao, WANG Zhipeng, SHI Bin. Research Ideas of the Efficacy Mechanism and Prospect Analysis of Traditional Chinese Manipulative Therapy on Treating Spinal Degenerative Diseases with Combination of Medicine and Industry [J]. Chinese General Practice, 2023, 26(33): 4118-4124.
[2]	XIN Gongkai, CONG Xin, YUAN Lei, CHENG Yuetong, NI Cuiping, ZHANG Weiwei, ZHANG Pingping, LIU Yu. Research Progress on Comprehensive Assessment Tools for the Elderly with Dementia [J]. Chinese General Practice, 2023, 26(33): 4103-4109.
[3]	ZHANG Siyu, ZHOU Yuqiu, DU Xiaohui, WANG Zhengjun. Advances in Duration of Untreated Psychosis and Its Early Intervention [J]. Chinese General Practice, 2023, 26(33): 4110-4117.
[4]	MA Liyuan, WANG Zengwu, FAN Jing, HU Shengshou. Interpretation of Report on Cardiovascular Health and Diseases in China 2022 [J]. Chinese General Practice, 2023, 26(32): 3975-3994.
[5]	MENG Jiangtao, YANG Siyu, SUN Lei, LEI Ruining, ZHAO Xiaoxia. Advances in the Prognostic Value of Diffusion Tensor Imaging with Motor Evoked Potential for Motor Function in Cerebral Infarction Patients with Hemiplegia [J]. Chinese General Practice, 2023, 26(32): 4098-4102.
[6]	WANG Jiaxin, ZHAO Yali. Domestic and International Assessment Tools for Medical Teamwork: a Systematic Review [J]. Chinese General Practice, 2023, 26(31): 3951-3962.
[7]	WEI Mengyu, WANG Jiajia, ZHANG Yingying, LI Chunyang, LI Jiansheng. Research Status of Patient-reported Outcome Assessment Tools for Obstructive Sleep Apnea [J]. Chinese General Practice, 2023, 26(30): 3725-3733.
[8]	YUAN Xiwei, NAN Yuemin. Research Progress of Structure, Function and Mechanism of Action of Mitofusin 2 in Liver Diseases [J]. Chinese General Practice, 2023, 26(30): 3841-3846.
[9]	XIAO Yuqian, BAI Yanjie, WANG Yan, CHEN Shuying, CHEN Limin, SUN Kexin, WAN Jun. Research Progress of Mitochondrial Transfer in Post-stroke Cognitive Impairment [J]. Chinese General Practice, 2023, 26(30): 3833-3840.
[10]	LIU Yu, YUE Ting, YANG Dongyu, ZHAO Zhongting, YANG Jibo, ZHU Tiantian. Research Progress on Mechanism of Autophagy in the Pathogenesis of Rheumatoid Arthritis [J]. Chinese General Practice, 2023, 26(29): 3710-3714.
[11]	PU Yu, ZHANG Jixiang, DONG Weiguo. Advances in Ferroptosis and Inflammatory Bowel Disease [J]. Chinese General Practice, 2023, 26(29): 3698-3703.
[12]	HUANG Qixian, WEN Yanting, HUANG Jun, LI Weibin, XU Yongneng, LIN Xiayi, WANG Haoxiang, WENG Fan, YANG Lianping. Prevalence of Dyslipidemia and Its Influencing Factors among Elderly Community Residents [J]. Chinese General Practice, 2023, 26(28): 3520-3525.
[13]	REN Yanfeng, LIU Shimeng, TAO Ying, CHEN Yingyao. A Systematic Review of Medication Preferences for Patients with Depression Based on Discrete Choice Experiment and Best-worst Scaling [J]. Chinese General Practice, 2023, 26(28): 3559-3564.
[14]	TANG Shilan, XIE Kexin, LIU Lingyu, QI Tiantian, YANG Yansui. Advances in Rehabilitation Outcomes and Care in Patients with Prolonged Disorders of Consciousness [J]. Chinese General Practice, 2023, 26(27): 3342-3348.
[15]	LIANG Xuemei, WANG Rui, ZHAO Yuhuan, XU Tianjiao, WANG Wei, SUN Weidong. Transcranial Low-level Laser Therapy: a Novel Treatment for Depression [J]. Chinese General Practice, 2023, 26(27): 3335-3341.